{"id":"anti-il2r-ab","safety":{"commonSideEffects":[{"rate":"10%","effect":"Anemia"},{"rate":"5%","effect":"Thrombocytopenia"},{"rate":"20%","effect":"Nausea"},{"rate":"15%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1821846","moleculeType":"Small molecule","molecularWeight":"676.71"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Anti-IL2R antibodies are a class of immunomodulatory drugs that target the interleukin-2 receptor (IL2R) to prevent T-cell activation and proliferation.","oneSentence":"Anti-IL2R antibody","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:09:56.385Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid Arthritis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT00693524","phase":"PHASE2","title":"Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-11","conditions":"Liver Transplantation","enrollment":94}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["daclizumab"],"phase":"phase_2","status":"active","brandName":"Anti-IL2R AB","genericName":"Anti-IL2R AB","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-IL2R antibody Used for Rheumatoid Arthritis, Psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}